<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02535572</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042678</org_study_id>
    <nct_id>NCT02535572</nct_id>
  </id_info>
  <brief_title>Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment</brief_title>
  <acronym>FEAST</acronym>
  <official_title>Focal Electrically-Administered Seizure Therapy (FEAST): Studies at Two Enrolling Sites to Further Test and Refine the Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Augusta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label investigation further evaluates the safety, efficacy and potential mechanisms&#xD;
      of action of a new form of electroconvulsive therapy (ECT). The investigators have recently&#xD;
      completed preliminary open-label studies with FEAST, first at Columbia University, and then&#xD;
      at the Medical University of South Carolina in Charleston (Nahas et al., 2013b). The&#xD;
      investigators have published the outcomes of the first 17 patients studied. One patient&#xD;
      withdrew from the study after a single titration session. After the course of FEAST (median&#xD;
      10 sessions), there was a 46.1 + 35.5% improvement in Hamilton Rating Scale for Depression&#xD;
      (HRSD24) scores compared to baseline (33.1 + 6.8, 16.8 + 10.9; P &lt; 0.0001). Eight of 16&#xD;
      patients met response criteria (≥50% decrease in HRSD24) and 5/16 met remission criteria&#xD;
      (HRSD24≤10). Patients achieved full re-orientation (4 of 5 items correct) in 5.5 + 6.4 min&#xD;
      (median time = 3.6 min), timed from when their eyes first opened after treatment. The&#xD;
      investigators have now studied 18 more patients (see results below), and we are completing&#xD;
      the study in the original IDE with another two more patients still to enroll.&#xD;
&#xD;
      This work allowed us to refine the treatment. For example, the investigators selectively&#xD;
      modified the electrode geometry to decrease interelectrode resistance. Additionally the&#xD;
      investigators modified the titration schedule, now only administering a standard 800 ma&#xD;
      ultrabrief pulse, and thus no longer titrating in the current domain.&#xD;
&#xD;
      In this next proposed trial we will continue to gather efficacy and safety data, and compare&#xD;
      these to a parallel non-randomized group receiving ECT standard of care.&#xD;
&#xD;
      ECT is typically delivered in a dynamically adaptive manner, with each person having a&#xD;
      different number of treatments, averaging between 8-12 treatment over 4-5 weeks. We thus have&#xD;
      to use imprecise time points such as 'at the end of the acute treatment course' rather than&#xD;
      specified dates or visits.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will provide preliminary evaluation of the following:&#xD;
&#xD;
        1. Further characterization of the efficacy of FEAST and the safety of the treatment.&#xD;
&#xD;
             1. The primary efficacy measure will be the 24-item Hamilton Rating Scale for&#xD;
                Depression. The changes in these scores from before to immediately following the&#xD;
                treatment course (typically after 4 weeks) will be compared in patients treated&#xD;
                with the FEAST methodology and matched to nonrandomized patients at our facilities&#xD;
                who were treated with conventional ECT methods (ultrabrief right unilateral [RUL]&#xD;
                ECT).&#xD;
&#xD;
             2. Acute and subacute cognitive side effects following FEAST will be assessed with a&#xD;
                brief neuropsychological battery. The primary acute measures will be the time to&#xD;
                return of orientation following seizure induction. The primary subacute measures&#xD;
                will be assessment of retrograde amnesia for autobiographical information. The&#xD;
                neuropsychological measures will be compared in the patients treated with the FEAST&#xD;
                methodology (under this IDE) and matched (but nonrandomized) patients who are&#xD;
                treated with conventional ECT methods (also covered under this IDE).&#xD;
&#xD;
             3. Safety will also be determined by examining the number and frequency of serious&#xD;
                adverse advents and adverse events.&#xD;
&#xD;
        2. Characterization of the focal nature of the seizure onset with FEAST and RUL ECT. We&#xD;
           will use two main methods to address the issue of focality.&#xD;
&#xD;
             1. Resting state fMRI before and after a course of FEAST (or conventional RUL ECT). We&#xD;
                will address whether FEAST causes changes in hyper connected prefrontal cortical&#xD;
                subcortical networks, and whether such an effect is more restricted to prefrontal&#xD;
                cortex with FEAST relative to conventional RUL ECT.&#xD;
&#xD;
             2. Peri-ictal EEG acquired immediately before, during and immediately after the FEAST&#xD;
                seizure. We will acquire this in all patients at all treatment sessions. Again, for&#xD;
                comparison, we will use identical EEG acquisition methods in patients treated with&#xD;
                conventional RUL ECT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">June 10, 2019</completion_date>
  <primary_completion_date type="Actual">June 10, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression</measure>
    <time_frame>From Baseline to end of acute course (typically after 4 weeks)</time_frame>
    <description>The 24-item Hamilton Rating Scale for Depression has a range score of 0-7 (no depression) 7-17(mild depression) 17-24 (moderate depression) 25 and higher (severe depression). The Hamilton Rating Scale for Depression has a range of 0-72.&#xD;
Lower score represents mild depression to no depression at all. A score of 21 or higher for clinical depression (inclusion criteria to participate in study).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Return to Orientation</measure>
    <time_frame>From Baseline to end of the acute course (typically after 4 weeks)</time_frame>
    <description>Acute and subacute cognitive side effects following FEAST will be assessed with a brief neuropsychological battery. The primary acute measures will be the time to return of orientation following seizure induction. The neuropsychological measures will be compared in the patients treated with the FEAST methodology (under this IDE) and matched (but nonrandomized) patients who are treated with conventional ECT methods (also covered under this IDE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retrograde Amnesia for Autobiographical Information Using CUAMI-SF Consistency Scores</measure>
    <time_frame>4 weeks</time_frame>
    <description>Columbia University Autobiographical Memory Interview (CUAMI-SF) assesses the percent consistency in responses and has a maximum of 100%, with lower percentages representing increasing inconsistency. In this interview subjects receive points for each question they answer at Baseline and again at study follow-up, and are graded on the consistency of their answers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>From the start of the study through the six month follow up</time_frame>
    <description>Safety will also be determined by examining the number and frequency of serious adverse advents and adverse events from the start of the study through the six month follow up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>FEAST</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the FEAST form of ECT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUL UB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FEAST</intervention_name>
    <description>FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
    <arm_group_label>FEAST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RUL UB</intervention_name>
    <description>This is right unilateral ultrabrief ECT, the standard of care.</description>
    <arm_group_label>RUL UB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Major Depressive Episode&#xD;
&#xD;
          -  Pretreatment Hamilton Depression Score &gt;21&#xD;
&#xD;
          -  ECT indicated&#xD;
&#xD;
          -  Willing and able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of schizophrenia, schizoaffective disorder, other functional psychosis, or&#xD;
             rapid cycling bipolar disorder&#xD;
&#xD;
          -  History of central nervous system illness or insult other than conditions associated&#xD;
             with psychotropic exposure (e.g., tardive dyskinesia)&#xD;
&#xD;
          -  Alcohol or substance abuse or dependence in the past year (DSM-V)&#xD;
&#xD;
          -  Secondary diagnosis of a delirium, dementia, or amnestic disorder (DSM-V), pregnancy,&#xD;
             or epilepsy&#xD;
&#xD;
          -  Requires especially rapid antidepressant response due to suicidality, psychosis,&#xD;
             inanition, psychosocial obligations, etc.&#xD;
&#xD;
          -  No anticonvulsant mood stabilizers (e.g., Depakote, Tegretol, Lamictal); No lithium;&#xD;
             No psychostimulants (e.g., Ritalin, Adderall);&#xD;
&#xD;
        Allowed medications during FEAST/ECT:&#xD;
&#xD;
        Antidepressants, including buproprion Atypical antipsychotics; Hypnotics for sleep;&#xD;
        Anxiolytics (limited to up to 3 mg equivalents/day lorazepam)&#xD;
&#xD;
          -  ECT in the past six months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark S George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgia Regents Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Brain Stimulation Division</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Nahas Z, Short B, Burns C, Archer M, Schmidt M, Prudic J, Nobler MS, Devanand DP, Fitzsimons L, Lisanby SH, Payne N, Perera T, George MS, Sackeim HA. A feasibility study of a new method for electrically producing seizures in man: focal electrically administered seizure therapy [FEAST]. Brain Stimul. 2013 May;6(3):403-8. doi: 10.1016/j.brs.2013.03.004. Epub 2013 Mar 16.</citation>
    <PMID>23518262</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 25, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2015</study_first_posted>
  <results_first_submitted>September 30, 2020</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 4, 2021</results_first_posted>
  <disposition_first_submitted>June 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 11, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 16, 2020</disposition_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electroconvulsive Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 5, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT02535572/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>48 participants were recruited, however only 41 subjects received treatment. 7 subjects withdrew before the treatment began for the following reasons:changed their mind about research (2), time contraints (3), financial reasons (1), no longer met inclusion criteria (1).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>FEAST</title>
          <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
        </group>
        <group group_id="P2">
          <title>RUL UB (Right Unilateral Ultrabrief Electroconvulsive Therapy)</title>
          <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The participants in baseline analysis were those that maintained inclusion criteria throughout the duration of the study. 2 participants were not counted in the baseline analysis population due to exclusionary circumstances.</population>
      <group_list>
        <group group_id="B1">
          <title>FEAST</title>
          <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
        </group>
        <group group_id="B2">
          <title>RUL UB</title>
          <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="19"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.15" spread="12.68"/>
                    <measurement group_id="B2" value="43.16" spread="16.44"/>
                    <measurement group_id="B3" value="44.17" spread="14.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression</title>
        <description>The 24-item Hamilton Rating Scale for Depression has a range score of 0-7 (no depression) 7-17(mild depression) 17-24 (moderate depression) 25 and higher (severe depression). The Hamilton Rating Scale for Depression has a range of 0-72.&#xD;
Lower score represents mild depression to no depression at all. A score of 21 or higher for clinical depression (inclusion criteria to participate in study).</description>
        <time_frame>From Baseline to end of acute course (typically after 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FEAST</title>
            <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
          </group>
          <group group_id="O2">
            <title>RUL UB</title>
            <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Depressive Symptoms as Assessed by Hamilton Rating Scale for Depression</title>
          <description>The 24-item Hamilton Rating Scale for Depression has a range score of 0-7 (no depression) 7-17(mild depression) 17-24 (moderate depression) 25 and higher (severe depression). The Hamilton Rating Scale for Depression has a range of 0-72.&#xD;
Lower score represents mild depression to no depression at all. A score of 21 or higher for clinical depression (inclusion criteria to participate in study).</description>
          <units>percentage of change in score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.83" spread="18.36"/>
                    <measurement group_id="O2" value="61.81" spread="20.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Return to Orientation</title>
        <description>Acute and subacute cognitive side effects following FEAST will be assessed with a brief neuropsychological battery. The primary acute measures will be the time to return of orientation following seizure induction. The neuropsychological measures will be compared in the patients treated with the FEAST methodology (under this IDE) and matched (but nonrandomized) patients who are treated with conventional ECT methods (also covered under this IDE).</description>
        <time_frame>From Baseline to end of the acute course (typically after 4 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FEAST</title>
            <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
          </group>
          <group group_id="O2">
            <title>RUL UB</title>
            <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Return to Orientation</title>
          <description>Acute and subacute cognitive side effects following FEAST will be assessed with a brief neuropsychological battery. The primary acute measures will be the time to return of orientation following seizure induction. The neuropsychological measures will be compared in the patients treated with the FEAST methodology (under this IDE) and matched (but nonrandomized) patients who are treated with conventional ECT methods (also covered under this IDE).</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56" spread="5.03"/>
                    <measurement group_id="O2" value="8.79" spread="5.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Retrograde Amnesia for Autobiographical Information Using CUAMI-SF Consistency Scores</title>
        <description>Columbia University Autobiographical Memory Interview (CUAMI-SF) assesses the percent consistency in responses and has a maximum of 100%, with lower percentages representing increasing inconsistency. In this interview subjects receive points for each question they answer at Baseline and again at study follow-up, and are graded on the consistency of their answers.</description>
        <time_frame>4 weeks</time_frame>
        <population>intent to treat sample</population>
        <group_list>
          <group group_id="O1">
            <title>FEAST</title>
            <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
          </group>
          <group group_id="O2">
            <title>RUL UB</title>
            <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Retrograde Amnesia for Autobiographical Information Using CUAMI-SF Consistency Scores</title>
          <description>Columbia University Autobiographical Memory Interview (CUAMI-SF) assesses the percent consistency in responses and has a maximum of 100%, with lower percentages representing increasing inconsistency. In this interview subjects receive points for each question they answer at Baseline and again at study follow-up, and are graded on the consistency of their answers.</description>
          <population>intent to treat sample</population>
          <units>percentage of consistent responses</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.64" spread="15.08"/>
                    <measurement group_id="O2" value="64.66" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Adverse Events</title>
        <description>Safety will also be determined by examining the number and frequency of serious adverse advents and adverse events from the start of the study through the six month follow up.</description>
        <time_frame>From the start of the study through the six month follow up</time_frame>
        <population>Participants that met inclusion criteria and are included in the analysis group</population>
        <group_list>
          <group group_id="O1">
            <title>FEAST</title>
            <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
          </group>
          <group group_id="O2">
            <title>RUL UB (Right Unilateral Ultrabrief Electroconvulsive Therapy)</title>
            <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Adverse Events</title>
          <description>Safety will also be determined by examining the number and frequency of serious adverse advents and adverse events from the start of the study through the six month follow up.</description>
          <population>Participants that met inclusion criteria and are included in the analysis group</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>muscle ache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events have been collected throughout the duration of the study, from the beginning of the treatments through the 6 month follow up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>FEAST</title>
          <description>Patients will receive the FEAST form of ECT&#xD;
FEAST: FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.</description>
        </group>
        <group group_id="E2">
          <title>RUL UB</title>
          <description>Patients will receive the standard of care, right unilateral ultrabrief ECT (RUL UB)&#xD;
RUL UB: This is right unilateral ultrabrief ECT, the standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Spontaneous Abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="35" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E2" events="50" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle ache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="32" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E2" events="46" subjects_affected="14" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>prolonged seizure</sub_title>
                <description>midazolam was required to stop a prolonged seizure in one participant</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>postictal agitation),</sub_title>
                <description>agitation post seizure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>postictal delirium</sub_title>
                <description>delirium post seizure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="108" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E2" events="99" subjects_affected="17" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Morgan Dancy</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>843-876-5141</phone>
      <email>maddoxm@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

